Current research on the treatment of primary sclerosing cholangitis

Ali, Ahmad H.; Carey, Elizabeth J.; Lindor, Keith D.

doi:10.5582/irdr.2014.01018

Cited by 27 publications

(14 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical features, however, can include jaundice, itching, abdominal pain, weight loss and fatigue . Treatment is largely symptomatic, and disease progression is seldom halted by steroid or immunotherapy . Interventional stenting is often required as fibrosis progresses but ultimately, after a mean time‐period of 12 years, end‐stage disease results in cirrhosis and decompensated liver failure requiring transplantation .…”

Section: Introductionmentioning

confidence: 99%

Bile duct basement membrane thickening in primary sclerosing cholangitis

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Bile duct basement membrane thickening in primary sclerosing cholangitis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…BTT-1023, a human monoclonal antibody against VAP1, will be assessed in the clinical study in patients with primary sclerosing cholangitis. This autoimmune liver disease is characterized by the progressive destruction of the hepatic bile ducts, which in turn leads to liver fibrosis and cholestasis [122]. Preclinical studies showed efficient binding of the antibody with VAP1 in the inflamed sites in vivo , as assessed by PET scans [121].…”

Section: Developments In Targeted Therapy Related To Liver Fibrosismentioning

confidence: 99%

Clinical Advancements in the Targeted Therapies against Liver Fibrosis

Bansal

Nagórniewicz

Prakash

2016

Mediators of Inflammation

View full text Add to dashboard Cite

Hepatic fibrosis, characterized by excessive accumulation of extracellular matrix (ECM) proteins leading to liver dysfunction, is a growing cause of mortality worldwide. Hepatocellular damage owing to liver injury leads to the release of profibrotic factors from infiltrating inflammatory cells that results in the activation of hepatic stellate cells (HSCs). Upon activation, HSCs undergo characteristic morphological and functional changes and are transformed into proliferative and contractile ECM-producing myofibroblasts. Over recent years, a number of therapeutic strategies have been developed to inhibit hepatocyte apoptosis, inflammatory responses, and HSCs proliferation and activation. Preclinical studies have yielded numerous targets for the development of antifibrotic therapies, some of which have entered clinical trials and showed improved therapeutic efficacy and desirable safety profiles. Furthermore, advancements have been made in the development of noninvasive markers and techniques for the accurate disease assessment and therapy responses. Here, we focus on the clinical developments attained in the field of targeted antifibrotics for the treatment of liver fibrosis, for example, small molecule drugs, antibodies, and targeted drug conjugate. We further briefly highlight different noninvasive diagnostic technologies and will provide an overview about different therapeutic targets, clinical trials, endpoints, and translational efforts that have been made to halt or reverse the progression of liver fibrosis.

show abstract

“…В терминальных стадиях ПСХ, а также при наличии дисплазии холангиоцитов или рецидивирующем бактериальном холангите, рекомендуется проведение трансплантации печени [33,34]. Рецидив ПСХ в транс-плантате наблюдается у 20-40% пациентов с ПСХ [38].…”

Section: первичный склерозирующий холангитunclassified

“…На данный момент исследование эффективности и безопасности таких препаратов проводится у животных моделей ПСХ. Согласно результатам этих работ, применение агонистов FXR сопровождается уменьшением степени выражен-ности воспаления в ткани печени, повреждения желчных протоков, степени развития фиброза печени [38].…”

Section: первичный склерозирующий холангитunclassified